Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoV-PlasGal: Convalescent Plasma for Early COVID-19
NCT05578391Phase 2Completed
- Sponsor
- Fundación Biomédica Galicia Sur
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundación Biomédica Galicia Sur. Primary endpoint: Requirement for oxygen therapy to maintain saturation >93% at 14 days. Started Jan 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05578391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578391.